The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study—Analysis of after cetuximab refractory.
Yoshimitsu Kobayashi
No relevant relationships to disclose
Hiraku Fukushima
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Takaya Kusumi
No relevant relationships to disclose
Ayako Doi
No relevant relationships to disclose
Yasushi Tsuji
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Minoru Uebayashi
No relevant relationships to disclose
Masahiko Koike
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Yasushi Sato
No relevant relationships to disclose
Tomoyuki Ohta
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Jun Konno
No relevant relationships to disclose
Kazuhiro Iwai
No relevant relationships to disclose
Yuh Sakata
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha